Literature DB >> 3882644

Non-Hodgkin's lymphomas of head and neck extranodal sites.

C Jacobs, R T Hoppe.   

Abstract

The initial staging, therapy and course of 156 patients with non-Hodgkin's lymphomas of head and neck extranodal sites were analyzed to determine whether they have a natural history which differs from primary nodal disease. The sites involved were: Waldeyer's ring-103 patients (tonsil-60, nasopharynx-25, base of tongue-18), and extralymphatic sites-53 patients (salivary gland-20, paranasal sinus-20, oral cavity-10, and larynx-3). Seventy-six percent had unfavorable histologies and 24% had favorable histologies. Fifty-three percent had pathologic Stages I-II and 47% had Stages III-IV. The 5-year survival was influenced by primary sites: salivary gland-61%, oral cavity-57%, tonsil-49%, base of tongue-47%, nasopharynx-36% and paranasal sinus-12%. The 5-year survival was also influenced by histology: unfavorable histologies-39%, favorable histologies-69%. The Ann Arbor staging system was more useful than TNM for determining outcome. For patients with Stage I-II unfavorable histologies treated with radiation alone, the 5-year survival was: involved field-24%, extended field-42%, total lymphoid irradiation-52%. The majority of patients who failed did so in extranodal sites. Forty-one patients with advanced disease received a variety of chemotherapy regimens as the sole treatment. There was a high percentage of CNS recurrence with paranasal sinus lymphoma, and CNS prophylaxis may be necessary. For head and neck extranodal lymphomas, limited radiation is inadequate, and combined modality programs should be considered.

Entities:  

Mesh:

Year:  1985        PMID: 3882644     DOI: 10.1016/0360-3016(85)90158-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL).

Authors:  D F Nelson
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

2.  Isolated skeletal muscle recurrence of the paranasal sinus lymphoma in complete remission.

Authors:  Hakan Karagol; Duygu Derin; Mert Basaran; Sevil Bavbek
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 3.  Non-Hodgkin's lymphoma. II: Management problems.

Authors:  S E O'Reilly; J M Connors
Journal:  BMJ       Date:  1992-07-04

4.  Extranodal lymphoma.

Authors:  M A Rashid; A R Mondal; P K Mondal; S Roy
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2001-04

5.  Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Min-Young Oh; Joo-Seop Chung; Moo-Kon Song; Ho-Jin Shin; Ho-Sup Lee; Sang-Min Lee; Gyeong-Won Lee; Su-Ee Lee
Journal:  Int J Hematol       Date:  2013-02-12       Impact factor: 2.490

6.  Imaging characteristics of primary laryngeal lymphoma.

Authors:  N A Siddiqui; Barton F Branstetter; B E Hamilton; L E Ginsberg; C M Glastonbury; H R Harnsberger; E L Barnes; E N Myers
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

7.  Small lymphocytic lymphoma obscuring microscopic tonsillar squamous cell carcinoma: an unknown occurrence with a known primary.

Authors:  Eugen C Minca; Saurin R Popat; Manpreet K Chadha; Mihai Merzianu
Journal:  Head Neck Pathol       Date:  2010-12-01

Review 8.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

9.  Ocular involvement in nasal natural killer T-cell lymphoma.

Authors:  Luca Cimino; Chi-Chao Chan; DeFen Shen; Luciano Masini; Fiorella Ilariucci; Maurizio Masetti; Silvia Asioli; Antonio Sartori; Luca Cappuccini
Journal:  Int Ophthalmol       Date:  2008-04-26       Impact factor: 2.031

10.  Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients.

Authors:  Wafa Allam; Nabil Ismaili; Sanaa Elmajjaoui; Bel K Elgueddari; Mohammed Ismaili; Hassan Errihani
Journal:  BMC Ear Nose Throat Disord       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.